Thinking of pursuing an accounting qualification? We explore the different roles you could be qualified for after completing ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

The Association of Accounting Technicians (AAT) is a globally recognised body that provides industry-leading qualifications ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...

Investors need to pay close attention to American Assets Trust (AAT) stock based on the movements in the options market ...

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.